Aura Biosciences
AURA on Nasdaq. Biological products, (no diagnostic substances). Market value $645m.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-16.15 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
Each dollar kept in the business earns -64 cents a year. Above 10 is good.
Quality score: 40 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$6.17 a share, 30% above its 1-year low
Over the past year the price has ranged from $4.73 to $9.53.
Pays no dividend
Prices from Tuesday’s close (6 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating margin | |||||
| Operating margin | n/a | n/a | n/a | n/a | n/a |
| Debt to equity | |||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares outstanding | |||||
| Shares outstanding | 0.03bn | 0.04bn | 0.05bn | 0.06bn | 0.10bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)Not enough data
- Profit backed by cash (accruals)No
- Debt0.00× equity
- Revenue growth, five yearsUnknown
- Buying back its own sharesNo, 254% more shares since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- A loss of $46 million, compared with a loss of $27 million a year ago.
- Over the past 12 months it spent $103 million more cash than it brought in, compared with $84 million a year earlier.
- 64% more shares than a year ago. Each share owns a bit less of the company.
- It has $68 million more cash than debt, down from $107 million a year ago.
| Quarter to | Amount |
|---|---|
| September 2024 | -$21m |
| December 2024 | -$26m |
| March 2025 | -$27m |
| June 2025 | -$27m |
| September 2025 | -$26m |
| December 2025 | -$26m |
| March 2026 | -$34m |
| June 2026 | -$46m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 30 March 2026
- Next quarterly (estimated, 10-Q)
- 10 November 2026
Who owns it
2 long-term investors we follow own it, unchanged from 2 last quarter. 146 funds in all.
- Platinum Investment ManagementPlatinum team
- Value
- $794,242
- Share of fund
- 0.2%
- Letko BrosseauLetko Brosseau team
- Value
- $200,930
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Platinum Investment ManagementPlatinum team | $794,242 | 0.2% | |
| Letko BrosseauLetko Brosseau team | $200,930 | <0.1% |
Largest holders overall
- TCG Crossover Management$68mNew
- Montanova Capital$51mAdded
- Frazier Life Sciences Management, L.P.$50mAdded
- Nantahala Capital Management$42mAdded
- Long Focus Capital Management$36mAdded
- BlackRock$33mAdded
- Adage Capital Partners GP, L.L.C.$33mCut
- Caligan Partners LP$31mAdded
- Vanguard Capital Management$29mAdded
- Fcpm III Services B.V.$29mNew
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
9 investors own more than 5%.
- David E. GoelPassive investor11.2%Since 16 May 2025
- Chen YuPassive investorat least 9.9%(filed with 4 related holders)Since 5 May 2026
- Adage Capital Management, L.P.Passive investorat least 8.4%(filed with 2 related holders)Since 30 June 2026
- Suvretta Capital Management, LLCPassive investorat least 7.6%+1.5 pts(filed with 2 related holders)Since 30 June 2025
- Frazier Life Sciences Public Fund, L.P.Passive investorat least 5.6%−0.7 pts(filed with 9 related holders)Since 30 June 2026
- ForGrowth III PA B.V.Passive investorat least 5.1%(filed with 2 related holders)Since 25 September 2026
- LONG FOCUS CAPITAL MANAGEMENT, LLCPassive investorat least 4.9%−1.7 pts(filed with 1 related holder)Since 30 June 2026
- LONG FOCUS CAPITAL MASTER, LTD.Passive investorat least 3.6%0.0 pts(filed with 2 related holders)Since 24 December 2024
- Rajesh Parekh, Ph.D.Passive investorat least 3.3%(filed with 5 related holders)Since 13 February 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- Frazier Life Sciences Public Overage Fund, L.P.Passive investorSold down below 5%Since 30 June 2025
- Matrix Capital Management Company LPPassive investorSold down below 5%Since 7 May 2026
- Eventide Asset Management, LLCPassive investorSold down below 5%Since 31 March 2025
| Holder | Stake | Since | |
|---|---|---|---|
David E. Goel Passive investor | 11.2% | 16 May 2025 | |
Chen Yu Passive investor | at least 9.9% (filed with 4 related holders) | 5 May 2026 | |
Adage Capital Management, L.P. Passive investor | at least 8.4% (filed with 2 related holders) | 30 June 2026 | |
Suvretta Capital Management, LLC Passive investor | at least 7.6%+1.5 pts (filed with 2 related holders) | 30 June 2025 | |
Frazier Life Sciences Public Fund, L.P. Passive investor | at least 5.6%−0.7 pts (filed with 9 related holders) | 30 June 2026 | |
ForGrowth III PA B.V. Passive investor | at least 5.1% (filed with 2 related holders) | 25 September 2026 | |
LONG FOCUS CAPITAL MANAGEMENT, LLC Passive investor | at least 4.9%−1.7 pts (filed with 1 related holder) | 30 June 2026 | |
LONG FOCUS CAPITAL MASTER, LTD. Passive investor | at least 3.6%0.0 pts (filed with 2 related holders) | 24 December 2024 | |
Rajesh Parekh, Ph.D. Passive investor | at least 3.3% (filed with 5 related holders) | 13 February 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
Frazier Life Sciences Public Overage Fund, L.P. Passive investor | Sold down below 5% | 30 June 2025 | |
Matrix Capital Management Company LP Passive investor | Sold down below 5% | 7 May 2026 | |
Eventide Asset Management, LLC Passive investor | Sold down below 5% | 31 March 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 6 sold $1m.
- Gibney Anthony SSee RemarksSold
- Date
- 16 June 2026
- Shares
- 12,824
- Price
- $6.42
- Value
- $82,330
- Kilroy ConorSee RemarksSold
- Date
- 16 April 2026
- Shares
- 11,738
- Price
- $7.02
- Value
- $82,401
- Kilroy ConorSee RemarksSold
- Date
- 17 February 2026
- Shares
- 12,079
- Price
- $5.05
- Value
- $60,999
- Plavsic MarkChief Technology OfficerSold
- Date
- 17 February 2026
- Shares
- 15,890
- Price
- $5.05
- Value
- $80,245
- Hopkins Janet JillChief Medical OfficerSold
- Date
- 17 February 2026
- Shares
- 20,401
- Price
- $5.06
- Value
- $103,229
- Elazzouzi AmySenior Vice President, FinanceSold
- Date
- 17 February 2026
- Shares
- 8,549
- Price
- $5.06
- Value
- $43,258
- de los Pinos ElisabetSee Remarks, DirectorSold
- Date
- 17 February 2026
- Shares
- 47,648
- Price
- $5.06
- Value
- $241,099
- Elazzouzi AmySenior Vice President, FinanceSold
- Date
- 20 January 2026
- Shares
- 1,581
- Price
- $4.86
- Value
- $7,684
- de los Pinos ElisabetSee Remarks, DirectorSold
- Date
- 20 January 2026
- Shares
- 16,928
- Price
- $4.86
- Value
- $82,270
- Hopkins Janet JillChief Medical OfficerSold
- Date
- 17 November 2025
- Shares
- 17,109
- Price
- $5.42
- Value
- $92,731
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 16 June 2026 | Gibney Anthony S See Remarks | Sold | 12,824 | $6.42 | $82,330 |
| 16 April 2026 | Kilroy Conor See Remarks | Sold | 11,738 | $7.02 | $82,401 |
| 17 February 2026 | Kilroy Conor See Remarks | Sold | 12,079 | $5.05 | $60,999 |
| 17 February 2026 | Plavsic Mark Chief Technology Officer | Sold | 15,890 | $5.05 | $80,245 |
| 17 February 2026 | Hopkins Janet Jill Chief Medical Officer | Sold | 20,401 | $5.06 | $103,229 |
| 17 February 2026 | Elazzouzi Amy Senior Vice President, Finance | Sold | 8,549 | $5.06 | $43,258 |
| 17 February 2026 | de los Pinos Elisabet See Remarks, Director | Sold | 47,648 | $5.06 | $241,099 |
| 20 January 2026 | Elazzouzi Amy Senior Vice President, Finance | Sold | 1,581 | $4.86 | $7,684 |
| 20 January 2026 | de los Pinos Elisabet See Remarks, Director | Sold | 16,928 | $4.86 | $82,270 |
| 17 November 2025 | Hopkins Janet Jill Chief Medical Officer | Sold | 17,109 | $5.42 | $92,731 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 30 Mar 2026, plus the 10-Q filed 11 Aug 2026 and 8 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
Cheap for a reason is the question the numbers cannot answer.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.